Skin biopsy test detects abnormalities of key biomarker in neurodegenerative disorders
Estimated to affect 2.5 million people in the US, synucleinopathies comprise four neurodegenerative disorders
Read More
Tag: Beth Israel Deaconess Medical Center
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
